Laser May Be Safer Than Bevacizumab in Babies With Acute-Phase ROP

Source: Medscape

Tuesday, September 19, 2017 | Medical Studies , Retina

Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy, as reported in Medscape.

"Our paper demonstrates long-term ocular effects from using an anti-VEGF (anti-vascular endothelial growth factor) drug such as bevacizumab for the treatment of acute-phase ROP. These effects, including abnormalities of the posterior pole and peripheral retina, are seen much more frequently than they are in laser-treated eyes," said coauthor Dr. Graham E. Quinn of the University of Pennsylvania Perelman School of Medicine, in Philadelphia.

Read the full article here.


You must be logged in to leave a comment.